Novo Nordisk Initiates Share Repurchase Program
Ticker: NONOF · Form: 6-K · Filed: Dec 2, 2024 · CIK: 353278
Sentiment: neutral
Topics: share-repurchase, regulation, capital-return
TL;DR
Novo Nordisk is buying back its own stock, following EU rules.
AI Summary
Novo Nordisk A/S announced on December 2, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance with European regulations MAR and Commission Delegated Regulation (EU) 2016/1052.
Why It Matters
This indicates the company is returning capital to shareholders, potentially signaling confidence in its financial health and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a share repurchase program, which is a common corporate action.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- November 11, 2024 (date) — Initiation date of share repurchase program
- December 2, 2024 (date) — Announcement date
- Regulation No 596/2014 (regulation) — Governing regulation for share repurchase
- Commission Delegated Regulation (EU) 2016/1052 (regulation) — Governing regulation for share repurchase
FAQ
When did Novo Nordisk initiate its share repurchase program?
Novo Nordisk initiated its share repurchase program on November 11, 2024.
What is the announcement date of this share repurchase program?
The announcement was made on December 2, 2024.
Under which regulations is the share repurchase program being conducted?
The program is being conducted in accordance with Article 5 of Regulation No 596/2014 and Commission Delegated Regulation (EU) 2016/1052.
What is the company's principal executive office address?
The principal executive offices are located at Novo Allé 1 DK-2880, Bagsvaerd, Denmark.
Is Novo Nordisk filing an annual report under Form 20-F or 40-F?
Novo Nordisk is filing an annual report under Form 20-F.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-02 08:48:32
Filing Documents
- f6k_120224.htm (6-K) — 25KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006645.txt ( ) — 165KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: December 2, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer